We hypothesized that the selective inhibition of STAT3 by HCB-5300 and HCB-5400 would mitigate colonic injury, suppress pro-inflammatory cytokine expression (e.g., IL-6), and improve histopathological outcomes in DSS-induced colitis. Here, STAT3 is linked to colitis.